What is Abbott Laboratories Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Dec. 2023,
Abbott Laboratories paid$259 Mil more to buy back shares than it received from issuing new shares.
It spent$939 Mil paying down its debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent$888 Mil paying cash dividends to shareholders.
It received$34 Mil on other financial activities.
In all, Abbott Laboratoriesspent$2,052 Mil on financial activities for the
three
months ended in Dec. 2023.
Abbott Laboratories Cash Flow from Financing Historical Data
The historical data trend for Abbott Laboratories's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Abbott Laboratories Cash Flow from Financing Chart
Abbott Laboratories Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Abbott Laboratories's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7,091 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (NYSE:ABT) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Abbott Laboratories's issuance of stock for the
three
months ended in Dec. 2023 was $0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Abbott Laboratories's repurchase of stock for the
three
months ended in Dec. 2023 was $-259 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Abbott Laboratories's net issuance of debt for the
three
months ended in Dec. 2023 was $-939 Mil.
Abbott Laboratories spent$939 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Abbott Laboratories's net issuance of preferred for the
three
months ended in Dec. 2023 was $0 Mil.
Abbott Laboratories paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Abbott Laboratories's cash flow for dividends for the
three
months ended in Dec. 2023 was $-888 Mil.
Abbott Laboratories spent$888 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Abbott Laboratories's other financing for the
three
months ended in Dec. 2023 was $34 Mil.
Abbott Laboratories received$34 Mil on other financial activities.
Abbott Laboratories Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Abbott Laboratories's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Abbott Laboratories (Abbott Laboratories) Business Description
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABT has been successfully added to your 